Step 1 topics → Biochemistry → Cellular Signaling Pathways

Cellular Signaling Pathways

USMLE Step 1 trap: Inverts Gs and Gi effects on adenylyl cyclase and cAMP levels. Gs stimulates adenylyl cyclase to increase cAMP; Gi inhibits adenylyl cyclase to decrease cAMP.

Cellular signaling pathways are the molecular relay systems that let extracellular signals control intracellular behavior. For USMLE Step 1, this topic comes up in pharmacology (receptor targets of drugs), physiology (hormone mechanisms), and pathology (oncogene mutations). The exam tests this at multiple levels: pure recall ('what does Gq activate?'), application ('a drug inhibits adenylyl cyclase — which G-protein does it mimic?'), and passage-based reasoning where a vignette describes a receptor mutation and you have to predict downstream effects.

The trickiest part is keeping Gs, Gi, and Gq straight — especially under pressure. Students frequently invert Gs and Gi, or they lump Gq in with Gs because 'they're both stimulatory.' They're not the same. Gq runs a completely separate second messenger system through phospholipase C, IP3, DAG, and calcium — no cAMP involved. The other major confusion is between RTKs and JAK-STAT receptors: both phosphorylate tyrosines, but RTKs have intrinsic kinase domains while JAK-STAT receptors borrow kinase activity from associated JAK proteins. Mixing these up costs easy points.

USMLE Step 1 loves asking you to trace a signal from ligand to final effector, or to identify which pathway is disrupted by a toxin, mutation, or drug. Understanding the logic of each pathway — not just memorizing it — is what lets you handle novel vignettes. The goal of this page is to make that logic explicit.

From real student decks
65%have cards covering this topic
30%have mature cards

Common misconceptions

Common mistake
Wrong: Gi increases cAMP by stimulating adenylyl cyclase.
Right: Gs stimulates adenylyl cyclase to increase cAMP; Gi inhibits adenylyl cyclase to decrease cAMP.
The names are the clue: Gs = stimulatory, Gi = inhibitory — both refer to their effect on adenylyl cyclase. Gs activates adenylyl cyclase, which converts ATP to cAMP, raising intracellular cAMP. Gi does the opposite: it inhibits adenylyl cyclase, so cAMP levels fall. Inverting these is one of the most common wrong answers on signaling questions, so cement the directionality now: Gs up, Gi down.
Common mistake
Wrong: Gq signals through cAMP like Gs.
Right: Gq activates phospholipase C, which cleaves PIP2 into IP3 (releases intracellular Ca2+) and DAG (activates protein kinase C), not cAMP.
Gq has nothing to do with cAMP — full stop. When Gq is activated, it stimulates phospholipase C (PLC), which cleaves the membrane lipid PIP2 into two separate second messengers: IP3 and DAG. IP3 travels to the ER and triggers calcium release into the cytoplasm; DAG stays at the membrane and activates protein kinase C (PKC). Think of Gq as running a parallel, calcium-based system that is mechanistically distinct from the Gs/cAMP/PKA axis.
Common mistake
Wrong: RTKs are active as monomers after ligand binding.
Right: Ligand binding induces RTK dimerization, which enables trans-autophosphorylation of tyrosine residues and downstream signaling.
A single ligand-bound RTK monomer is not sufficient for activation — dimerization is the required next step. When two receptor monomers come together, each one phosphorylates specific tyrosine residues on the other (trans-autophosphorylation), creating docking sites for downstream signaling proteins. Without dimerization, those tyrosines never get phosphorylated and the signal doesn't propagate. This is also why some RTK mutations cause constitutive dimerization and unregulated cell growth — a high-yield oncology connection.
Common mistake
Wrong: JAK-STAT receptors have intrinsic kinase activity like RTKs.
Right: JAK-STAT receptors lack intrinsic kinase activity and rely on associated JAK kinases that phosphorylate STAT proteins upon receptor dimerization.
RTKs carry their own kinase domain built into the receptor protein itself — they are self-sufficient. JAK-STAT receptors do not have this; their cytoplasmic tails lack intrinsic kinase activity. Instead, they rely entirely on JAK kinases that are non-covalently associated with the receptor. When the receptor dimerizes upon ligand binding, the JAKs are brought close enough to phosphorylate each other and then the STAT proteins. Same downstream outcome (tyrosine phosphorylation), completely different structural setup — and the exam will exploit that distinction.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the GPCR second messenger cascades: Gs stimulates adenylyl cyclase to raise cAMP; Gi inhibits adenylyl cyclase to lower cAMP; Gq activates phospholipase C to generate IP3 and DAG — and be able to predict downstream effects when any of these are activated or blocked.
  2. Know how RTKs are activated: ligand binding causes receptor dimerization, which enables trans-autophosphorylation of tyrosine residues, which then recruits downstream signaling proteins like RAS — and recognize which ligands (growth factors, insulin, EGF, PDGF) use this receptor type.
  3. Know how JAK-STAT signaling works: cytokine binds receptor lacking its own kinase activity, receptor dimerizes, associated JAK kinases phosphorylate each other and then phosphorylate STAT proteins, which dimerize and translocate to the nucleus to regulate transcription — and know which cytokines and hormones (EPO, GH, prolactin, interferons, many interleukins) use this pathway.

Can you avoid these mistakes?

A patient is given a drug that activates a Gi-coupled receptor. What happens to intracellular cAMP levels, and what enzyme is directly affected?
Epidermal growth factor (EGF) binds its receptor. Walk through each step from ligand binding to activation of RAS — at which step does trans-autophosphorylation occur, and why is dimerization necessary?
A hormone activates a Gq-coupled receptor. List, in order, the second messengers produced and the immediate downstream effectors each one activates. Does cAMP appear anywhere in this pathway?
Erythropoietin (EPO) signals through the JAK-STAT pathway, while insulin signals through an RTK. Both result in tyrosine phosphorylation — what is the key structural difference between these two receptor types that explains how each achieves this?

Related topics

Nucleotide and Nucleic Acid Structure DNA Replication DNA Repair Pathways Mutations and Their Consequences

See how your Anki deck covers this topic.

Upload your deck for a free audit →